
    
      Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19
      Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia or CD19+ B-ALL patients and
      determine the MTD,LTD and the best dosage.
    
  